After an unusual review rejection, the FDA reverses course—a regulatory whiplash that could raise concerns about regulatory consistency.
The Eucalyptus deal deepens global reach as diversification beyond compounded GLP-1s in the US becomes urgent.
As AI tools steer more healthcare decisions, providers and insurers must target high-value use cases, carefully vet vendors, and lock in governance early.
Healthcare and pharma marketers should ramp up social listening and host expert Ask Me Anything sessions to drive engagement without feeling intrusive.
The FDA’s plans for broader access of medications could boost convenience, but also raise safety risks and drug costs.
Doctors watch less TV than the average US adult, but favor CTV and on-demand—which are prime time for targeted pharma messaging.
But as competition intensifies, high traffic isn’t enough—brands must pair visibility with proven product efficacy to convert surging consumer interest into loyalty.
Fraudulent care messages drive stress and confusion, pushing brands to rethink patient communication strategies.
India’s GLP-1 rollout next month signals tougher pricing ahead for GLP-1 brands.
Rising FDA enforcement pushes drugmakers to revisit messaging and risk framing.
Doctors must reassert personalized nutrition advice, while food brands should highlight their better-for-you offerings.
Convenience and drug savings will attract some consumers, but Amazon hasn’t yet been able to disrupt the pharmacy space.
The FDA denied an application for its flu vaccine, deepening regulatory doubt and complicating forecasts for vaccine-driven revenue growth.
Consumers show cautious interest, but only if tools are clinically validated, transparent, and privacy secure.
Novo’s lawsuit and regulator warnings signal a crackdown on compounded GLP-1s across telehealth.
Aetna is finally finding its footing, managing medical costs more effectively, even as industry-wide pressures remain.
Its recent Pfizer and TrumpRx partnerships show how pharma companies are betting on D2C distribution and consumer-facing pricing.
Big linear TV won’t wow all viewers, but the massive reach can still drive research, provider talks, and care.
The cash-pay discount hub will offer fewer drugs than GoodRx and have limited reach, but drugmakers must still promote it to drive prescription volumes, especially for uninsured drugs.
Apple isn’t abandoning AI-powered health guidance, but it’s likely holding back until the tech is useful enough to deliver real value.